news

07-09-2018

First half results 2018

Consolidated turnover of Euro 278.3 million and adjusted gross margin of 39.0%

read more 

17-07-2018

Updated Bylaws

Kedrion’s Extraordinary Meeting of Shareholders approves the amendment of the Company’s Bylaws

read more 

28-05-2018

Shareholders’ Agreement

Sestant Internazionale, Sestant and FSI Investimenti sign a new Shareholders’ Agreement concerning Kedrion

read more 

22-05-2018

FY 2017 Results General Investor Call

Friday 25 May 2018 – 09.00 GMT / 10.00 CET

read more 

27-04-2018

Annual General Meeting of Shareholders 2018

Kedrion’s shareholders approve financial statements for fiscal year 2017, confirm board of directors

read more 

29-03-2018

Annual Results 2017

Consolidated turnover of Euro 602.5 million and adjusted EBITDA of Euro 139.9 million, up 31.6%

read more 

31-01-2018

Opening of an antitrust investigation

read more 

31-10-2017

Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy

Agreement covers complete INTERCEPT product line: platelets, plasma, and red blood cells

read more 

25-08-2017

Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

The product is approved for post-exposure prophylaxis against rabies infection

read more 

11-08-2017

First half results 2017

First half consolidated turnover of EUR 271.7 M and adjusted EBITDA increase by 29.0% compared to the same period in 2016, with a margin of 24.1%

read more 

Pages